Securities code: Suzhou New District Hi-Tech Industrial Co.Ltd(600736) stock abbreviation: Suzhou New District Hi-Tech Industrial Co.Ltd(600736) Announcement No.: 2022008 Suzhou New District Hi-Tech Industrial Co.Ltd(600736)
Announcement of abnormal fluctuations in stock trading
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
Suzhou New District Hi-Tech Industrial Co.Ltd(600736) (hereinafter referred to as “the company”) shares had a cumulative deviation of 20% from the closing price on March 16, March 17 and March 18, 2022, which belongs to the abnormal fluctuation of stock trading stipulated in the trading rules of Shanghai Stock Exchange.
The company is planning to implement cash capital increase (hereinafter referred to as “this capital increase”) on Suzhou Medical Device Industry Development Co., Ltd. (hereinafter referred to as “medical device industry company”) and realize the holding and consolidation of the transaction object. At present, the audit evaluation is under way, and the capital increase price, capital increase amount and shareholding ratio of the company after capital increase have not been determined, The company has not signed any intentional agreement related to this capital increase with the medical device industry company or its current shareholders.
This capital increase constitutes a related party transaction stipulated in the stock listing rules of Shanghai Stock Exchange and is not expected to constitute a major asset reorganization stipulated in the administrative measures for major asset reorganization of listed companies. It needs to be submitted to the board of directors and the general meeting of shareholders for deliberation, and needs to be approved by the state-owned assets supervision and administration department. There is uncertainty in the implementation progress. After the capital increase, the operating income, net profit and other financial indicators of the medical device industry company account for a small proportion of the company as a whole, which is not expected to have a significant impact on the company’s short-term performance and lead to significant changes in the company’s main business and fundamentals.
After the company’s self-examination and verification with the controlling shareholder and actual controller of the company, as of the disclosure date of this announcement, there are no other major matters or information that should be disclosed but not disclosed.
1、 Details of abnormal fluctuations in stock trading
The deviation of the closing price of the company’s shares has reached 20% in three consecutive trading days on March 16, March 17 and March 18, 2022, which belongs to the abnormal fluctuation of stock trading stipulated in the trading rules of Shanghai Stock Exchange.
2、 Relevant information concerned and verified by the company
In view of the abnormal fluctuation of stock trading, the company has checked the relevant matters, and now the relevant information is explained as follows:
（1） Production and operation
At present, the company’s operation is normal, the market environment or industrial policies have not changed significantly, and no major contracts have been signed recently.
（2） Major events
The company is planning to implement cash capital increase for medical device industry companies, and realize holding and consolidation of transaction objects. At present, the audit evaluation is under way, and the capital increase price, amount and shareholding ratio of the company after the capital increase have not been determined. The company has not signed an intentional agreement related to the capital increase with the medical device industry company or its current shareholders.
Suzhou Su Hi Tech Group Co., Ltd., the current controlling shareholder of the medical device industry company, is the controlling shareholder of the company. According to the stock listing rules of Shanghai Stock Exchange, this capital increase will constitute a related party transaction.
Audited by Suzhou Branch of Tianheng Certified Public Accountants (special general partnership), as of the end of 2020, the total assets of the medical device industry company were 2.289 billion yuan, and the net assets attributable to the shareholders of the parent company were 530 million yuan; In 2020, the medical device industry company realized an operating income of 593662 million yuan and a net profit attributable to the shareholders of the parent company of 8.9716 million yuan.
Based on the audited financial data of the medical device industry company in 2020, it is estimated that this capital increase does not constitute a major asset reorganization specified in the administrative measures for major asset reorganization of listed companies.
In addition, as of the disclosure date of this announcement, the company, its controlling shareholders and actual controllers have no other major events that affect the abnormal fluctuation of the company’s stock trading, and there are no major information that should be disclosed but not disclosed involving the company, including but not limited to major asset restructuring, share issuance, acquisition, debt restructuring, business restructuring, asset divestiture, asset injection, share repurchase, equity incentive, bankruptcy reorganization, major business cooperation The introduction of strategic investors and other major issues.
（3） Media reports, market rumors and hot concepts
The company did not find any media reports or market rumors that may or have had an impact on the stock trading price, and did not involve hot concept matters, etc.
（4） Other stock price sensitive information
The company has not found any other major events that may have a great impact on the share price of the listed company, and the directors, supervisors, senior managers and controlling shareholders of the company have not bought or sold the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Relevant risk tips
（1） Secondary market transaction risk
The company’s share price has been trading for three consecutive days, with large short-term fluctuations. As of the closing on March 18, 2022, the company’s rolling P / E ratio is 16.80; According to the data released on the website of China Securities Index Co., Ltd., the rolling P / E ratio of the industry classification “K real estate” of the CSRC to which the company belongs is 7.20, and the rolling P / E ratio of the company is higher than the industry average level. Please pay attention to the transaction risk of the secondary market.
（2） Progress risk of this capital increase
The capital increase price, amount and shareholding ratio of the company after the capital increase have not been determined, and the company has not signed an intentional agreement related to the capital increase with the medical device industry company or its current shareholders; This capital increase constitutes a related party transaction stipulated in the stock listing rules of Shanghai Stock Exchange and is not expected to constitute a major asset reorganization stipulated in the administrative measures for major asset reorganization of listed companies. It needs to be submitted to the board of directors and the general meeting of shareholders for deliberation, and needs to be approved by the state-owned assets supervision and administration department. There is uncertainty in the implementation progress.
（3） Impact on Listed Companies
After the capital increase, the operating income, net profit and other financial indicators of the medical device industry company account for a small proportion of the company as a whole, which is not expected to have a significant impact on the company’s short-term performance and lead to significant changes in the company’s main business and fundamentals.
4、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirmed that, except for the capital increase, the company has no other matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange or the planning, negotiation, intention and agreement related to such matters, and the board of directors has not been informed of the matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange Information that may have a great impact on the trading price of the company’s shares and their derivatives; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
It is hereby announced.
Suzhou New District Hi-Tech Industrial Co.Ltd(600736) board of directors
March 19, 2022
